Zhang Dapeng, Li Sha, Wang Ning, Tan Hor-Yue, Zhang Zhimin, Feng Yibin
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Front Microbiol. 2020 Feb 25;11:301. doi: 10.3389/fmicb.2020.00301. eCollection 2020.
Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.
新出现的研究结果表明,肠道微生物群与肺部之间存在重要的相互作用,这被称为肠-肺轴。大量研究观察到,在包括过敏、哮喘、慢性阻塞性肺疾病、囊性纤维化和肺癌在内的肺部疾病中存在肠道紊乱。近年来,研究肠道微生物群如何影响其他远处器官备受关注。尽管尚未完全明确这种紊乱是肺部疾病的原因还是结果,但肠道微生物种类和代谢产物的改变已与免疫反应、炎症变化以及肺部疾病发展相关联。在本文中,我们系统地综述了肠道微生物群和代谢产物组成变化在肺部疾病中的作用及潜在机制。特别强调了肠-肺轴在介导免疫反应和重塑炎症方面的作用。此外,我们还讨论了将调控肠道微生物群和代谢产物作为肺部疾病治疗方法的策略潜力。